project id: TCGA-PRAD; case submitter id: TCGA-EJ-A7NN; source center: 23; state: released; a260 a280 ratio: 1.85; normal tumor genotype snp match: Yes; ribosomal rna 28s 16s ratio: 1.02; rna integrity number: 7.5; age at index: 61; days to birth: -22499; ethnicity: not reported; gender: male; race: white; vital status: Alive; year of birth: 1952; age at diagnosis: 22499; ajcc clinical m: M0; ajcc clinical t: T3b; ajcc pathologic n: N1; ajcc pathologic t: T3b; classification of tumor: not reported; days to diagnosis: 0; days to last follow up: 197.0; icd 10 code: C61; last known disease status: not reported; morphology: 8140/3; primary diagnosis: Adenocarcinoma, NOS; primary gleason grade: Pattern 4; prior malignancy: no; prior treatment: No; progression or recurrence: not reported; secondary gleason grade: Pattern 3; site of resection or biopsy: Prostate gland; synchronous malignancy: No; tissue or organ of origin: Prostate gland; tumor grade: Not Reported; year of diagnosis: 2013; treatment or therapy: no; alcohol history: Not Reported; is ffpe: false; composition: Not Reported; days to collection: 191; initial weight: 240.0; sample id: fbcfe148-21f4-4a60-9343-2a32d9993ca1; sample submitter id: TCGA-EJ-A7NN-01A; portion id: df7e2ed0-eda6-474b-9b34-d56adfaccfdb; portion submitter id: TCGA-EJ-A7NN-01A-11; slide id: 0076efca-59c3-4a79-a6c6-0312470a6162; slide submitter id: TCGA-EJ-A7NN-01A-01-TSA; percent lymphocyte infiltration: 0.0; percent monocyte infiltration: 0.0; percent necrosis: 0.0; percent neutrophil infiltration: 0.0; percent normal cells: 20.0; percent stromal cells: 10.0; percent tumor cells: 70.0; percent tumor nuclei: 80.0; section location: TOP;